Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript

Core Points - Pfizer is conducting a clinical development strategy spotlight on the PD-1 VEGF bispecific PF-4404 [1] - The Pfizer Pflash series aims to provide educational insights into the company's pipeline, products, and personnel [2] - Each session in the series focuses on a specific product, therapeutic area, or growth initiative, allowing interaction with business leaders [3]